Portal de Periódicos da CAPES

Bone union‐promoting effect of romosozumab in an ovariectomized rat posterolateral lumbar fusion model

2024; Wiley; Volume: 42; Issue: 8 Linguagem: Inglês

10.1002/jor.25834

1554-527X

Kohei Okuyama, Kazuhide Inage, Geundong Kim, Tomohito Mukaihata, Ikuko Tajiri, Yasuhiro Shiga, Masahiro Inoue, Yawara Eguchi, Miyako Suzuki‐Narita, Takuma Otagiri, Ryuto Tsuchiya, Takahisa Hishiya, Takahito Arai, Noriyasu Toshi, Soichiro Tokeshi, Susumu Tashiro, Shuhei Ohyama, Noritaka Suzuki, Takeo Furuya, Satoshi Maki, Junichi Nakamura, Shigeo Hagiwara, Yuuya Kawarai, Yasuchika Aoki, Toshiaki Kotani, Masao Koda, Hiroshi Takahashi, Tsutomu Akazawa, Seiji Ohtori, Sumihisa Orita,

Bone Metabolism and Diseases

Spinal fixation surgery has been increasingly performed in patients with osteoporosis. Romosozumab, a drug that was introduced in Japan recently, is known to possibly promote bone healing. However, few studies have reported the therapeutic effects of romosozumab in clinical practice in Japan. Therefore, here, we investigated the effects of romosozumab dosage on bone fusion promotion using an ovariectomized rat spinal fusion model. Eight-week-old female Sprague-Dawley rats were matched by body weight and divided into three groups: 1.0 romosozumab (R) group (Evenity®, 25 mg/kg), 1/10R group (Evenity®, 2.5 mg/kg), and control (C) group (saline). Subcutaneous injections were administered twice a week for 8 weeks postoperatively. Computed tomography scans were performed every 2 weeks from the time of surgery till 8 weeks postoperatively. The mean fusion rates in terms of volume were significantly higher in the R groups [1/10R, 1.0R] than in the C group from 4 weeks postoperatively. The rate of increase was significantly higher in the 1.0R group from 4 weeks postoperatively and in the 1/10R group from 6 weeks postoperatively, than in the C group. The proportion of trabecular bone area was approximately 1.5 times higher in the R groups than in the C group. No significant differences were observed between the R groups. Our results suggest that romosozumab stimulates bone growth at the graft site, and similar effects were achieved at 1/10 of the standard dosage.